Sage Therapeutics Inc [SAGE] stock is trading at $11.73, up 6.39%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SAGE shares have gain 10.50% over the last week, with a monthly amount glided 7.66%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sage Therapeutics Inc [NASDAQ: SAGE] stock has seen the most recent analyst activity on May 29, 2024, when Robert W. Baird initiated its Neutral rating and assigned the stock a price target of $15. Previously, Citigroup started tracking the stock with Sell rating on May 29, 2024, and set its price target to $8. On April 17, 2024, downgrade downgraded it’s rating to Underperform and revised its price target to $14 on the stock. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $21 on December 12, 2023. Needham downgraded its rating to a Hold. Goldman downgraded its rating to Neutral for this stock on August 08, 2023, but kept the price target unchanged to $22. In a note dated August 08, 2023, Canaccord Genuity downgraded an Hold rating on this stock and revised its target price from $64 to $21.
Sage Therapeutics Inc [SAGE] stock has fluctuated between $9.76 and $49.74 over the past year. Currently, Wall Street analysts expect the stock to reach $47.65 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $11.73 at the most recent close of the market. An investor can expect a potential return of 306.22% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
Sage Therapeutics Inc [NASDAQ:SAGE] reported sales of 91.06M for the trailing twelve months, which represents a growth of 139.89%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -5.95%, Pretax Profit Margin comes in at -5.53%, and Net Profit Margin reading is -5.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.61 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.28 points at the first support level, and at 10.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.13, and for the 2nd resistance point, it is at 12.52.
Ratios To Look Out For
For context, Sage Therapeutics Inc’s Current Ratio is 12.22. As well, the Quick Ratio is 12.22, while the Cash Ratio is 2.82. Considering the valuation of this stock, the price to sales ratio is 7.76, the price to book ratio is 1.00.
Transactions by insiders
Recent insider trading involved Barrett Elizabeth, Director, that happened on Aug 09 ’23 when 2000.0 shares were purchased.
